Thaçi D, Körber A, von Kiedrowski R, et al. - In this PROSPECT study, an ongoing 24-week, single-cohort, non-interventional study, researchers evaluated prior and concomitant psoriasis treatments and transition periods in patients receiving secukinumab, as well as reported interim efficacy and safety data for secukinumab in the context of prior and concomitant treatments. Participants in the study were 1,988 patients (mean age was 48.1 ± 13.7 years) with moderate to severe psoriasis with a decision to receive secukinumab 300 mg. Data reported that mean baseline Psoriasis Area and Severity Index score was 17.7 ± 12.5. 90.9% of subjects had prior systemic treatment. In 44.3% of subjects, concomitant treatment was recorded. The efficacy and safety of secukinumab were comparable to that seen in the clinical trial program of phase 2/3 secukinumab. There were no unexpected safety signals.